To discuss the burden of metabolic dysfunction-associated steatotic liver disease (MASLD) in women, the impact of estrogen deficiency on MASLD development, and potential sex-specific therapeutic strategies, including hormone replacement therapy (HRT) and lifestyle modifications.
Key Findings:
MASLD prevalence increases significantly in women post-menopause, comparable to or exceeding that of men, with studies indicating a prevalence rate of up to 30%.
Estrogen deficiency is strongly implicated in the development and progression of MASLD, with evidence showing a direct correlation between low estrogen levels and increased liver fat accumulation.
Current treatment options for MASLD are not tailored for women, highlighting a gap in clinical research that needs to be addressed.
Interpretation:
Estrogen plays a critical role in regulating hepatic metabolism; its deficiency post-menopause significantly contributes to the increased risk and severity of MASLD in women, necessitating targeted interventions.
Limitations:
Women over 50 are underrepresented in clinical studies of liver disease, which may skew treatment efficacy and safety data.
The effects of HRT on MASLD have not been rigorously tested, leaving a critical gap in understanding its potential benefits or risks.
Conclusion:
There is a pressing need for tailored treatment strategies for MASLD in postmenopausal women, and further research is urgently required to understand the role of HRT in this context.
